Skip to main content
Menu

Sepsis - Quarterly Reports

List of quarterly reports on Sepsis

Sepsis Research Analysis

Q2 2026 sepsis research converged on host-directed control of inflammation and injury, rapid resistance diagnostics, and organ-specific metabolic therapy. April inaugurated an inflammasome-focused wave with an LRR-binding NLRP3 inhibitor (LOC14) and dual NLRP3–NCF1 redox targeting, which set the stage for May’s repurposed NLRP3 inhibitor ciclopirox with immediate translational potential. Cross-cutting immunometabolism advanced through discovery that itaconate alkylates AIM2 to trigger macrophage

Sepsis Research Analysis

Q1 2026 sepsis research converged on biology-informed triage, rapid bedside subphenotyping, and host-directed therapeutics. Pragmatic clinical implementation advanced with procalcitonin-guided ED workflows reducing 28-day mortality and a 1-hour IL-6/sTNFR1+bicarbonate panel enabling ARDS subphenotype assignment for precision enrollment. Parsimonious biomarker frameworks (cDIP) operationalized immune dysregulation and identified steroid-responsive patients, while multi-omic risk enrichment (BEYON

Sepsis Research Analysis

Q4 2025 sepsis research coalesced around precision stratification, time-resolved response monitoring, and mechanistically anchored therapeutic axes. A rapid host transcriptomic signature enabled 24-hour readouts of antibiotic response and aligned with interpretable, routine-lab AI tools that defined coagulation–inflammation subphenotypes for testable treatment-effect hypotheses. A goal-directed multi-omics framework operationalized predictive enrichment for fluids and immunomodulation, while vas

Sepsis Research Analysis

Across 2025-Q3, sepsis research coalesced around host-directed, mechanistically grounded strategies and rigorous methodological standards. Immunometabolic drivers of organ dysfunction were clarified, linking lactate-driven HADHA lactylation and phospholipid-stabilized HIF-1α to mitochondrial suppression and septic cardiomyopathy. Chromatin-level immune restraint (nSB–NFIL3) and a brain–adrenal–lung neuroimmune circuit (afferent VNS) outlined drug- and device-traceable pathways. Systems glycoprot

Sepsis Research Analysis

Q2 2025 sepsis research converged on precision endotyping, host–pathogen mechanistic checkpoints, and practical stewardship. A Cell human proteome atlas enabled organ-origin inference from plasma, while cross-species multi-omics unified early metabolite signals with mitochondrial dysfunction for presymptomatic detection. Mechanistic work mapped druggable pathways across cell death (endothelial ferroptosis, caspase-11 pyroptosis), neuroimmune-immunometabolic axes (DRD2–TLR4–ACOD1–PD-L1), and host

Sepsis Research Analysis

Q1 2025 sepsis research coalesced around host-directed biology, data-driven hemodynamics, and within-host pathogen ecology. Foundational mechanistic work linked endothelial ferroptosis and platelet immunometabolism to organ injury, while microbiome–pathogen–host axes (AhR antagonism by enterobactin) and TLR4–ROS–driven gut blooms reframed infection susceptibility during systemic inflammation. An externally validated reinforcement-learning policy for vasopressin timing suggested practice-ready ch